Está usando un navegador no compatible.
Es posible que algunas características de este sitio no funcionen correctamente. Para tener una experiencia de usuario óptima, vea este sitio en Chrome, Firefox, Safari o Edge.

Congresos

Materiales de congresos

Tenga acceso a resúmenes, pósteres y presentaciones de los siguientes congresos

Septiembre 2023

Sociedad Española de Oncología Médica (SEOM)

Septiembre 2023

PTHiT (Sociedad Polaca de Hematología y Medicina Transfusional)

Septiembre 2023

World Conference on Lung Cancer (WCLC)

Septiembre 2023

KSMO (Sociedad Coreana de Oncología Médica)

Agosto 2023

Asia-Pacific Gastroenterology Cancer Summit (APGCS)

Agosto 2023

International Society for Pharmacoepidemiology (ICPE)

Agosto 2023

American Society of Clinical Oncology - Breakthrough (ASCO Breakthrough)

American Society of Clinical Oncology - Breakthrough (ASCO Breakthrough)

August 2023 (Yokohama, Japan)
Julio 2023

Translational Summit on Hematologic Malignancies (DAVA Oncology Meetings)

Junio 2023

WCGI (World Congress on Gastrointestinal Cancer)

Junio 2023

Health Technology Assessment international (HTAi)

Junio 2023

European Association for the Study of the Liver (EASL)

Junio 2023

ICML (International Conference on Malignant Lymphoma)

ICML (International Conference on Malignant Lymphoma)

Junio 2023 (Lugano, Suiza)

Resúmenes

A meta-analytic endpoint validation of surrogates used in clinical trials evaluating the efficacy of therapies in patients with chronic lymphocytic leukemia (CLL) A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL First interim analysis of a phase 1 study of zanubrutinib (zanu) + lenalidomide (len) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE Long-term efficacy and safety of zanubrutinib (ZANU) in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 versus lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) vs ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL) Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) CLL/SLL: extended follow-up of the SEQUOIA study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B-cell malignancies: Post hoc analysis of a large clinical trial safety database Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life
Junio 2023

EHA (Asociación Europea de Hematología)

EHA (Asociación Europea de Hematología)

Junio de 2023 (Fráncfort, Alemania)

Pósteres

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies BGB-16673, a BTK degrader, overcomes on-target resistance from BTK inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors Characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database Comparative efficacy of zanubrutinib versus rituximab in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC) First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Health-relayed quality of life in patients with Waldenström macroglobulinemia (WM) treated with zanubrutinib vs ibrutinib: results from the phase 3 ASPEN trial long-term follow-up Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial Matching-adjusted indirect comparison (MAIC) of zanubrutinib versus ibrutinib in relapsed/refractory marginal zone lymphoma (R/R MZL) Real-world treatment patterns of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma in community oncology practices in the United States Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)

Resúmenes

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies BGB-16673, a BTK degrader, overcomes on-target resistance from BTK inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors (BTKi) Characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database Comparative efficacy of zanubrutinib (zanu) versus rituximab (rtx) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC) Efficacy and safety of once daily (QD) vs twice daily (BID) zanubrutinib for patients with various B-cell malignancies: a comparative summary of clinical data and exposure-response analysis First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): results from the phase 3 ASPEN trial long-term follow-up Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Matching-adjusted indirect comparison (MAIC) of zanubrutinib (zanu) versus ibrutinib (ibru) in relapsed/refractory marginal zone lymphoma (R/R MZL) Persistence with oral therapy as reflection of actual compliance for chronic lymphocytic leukemia (CLL) - a national prescribed drug and patient registered study from Sweden Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US) The meta-analytic endpoint validation of surrogates used in clinical trials evaluating the efficacy of therapies in patients with chronic lymphocytic leukemia Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Junio 2023

ASCO (Sociedad Estadounidense de Oncología Clínica)

ASCO (Sociedad Estadounidense de Oncología Clínica)

Junio de 2023 (Chicago, Illinois, EE. UU.)

Pósteres

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC) First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS) MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 European/North American (EU/NA) subgroup Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a phase Ib/II study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed or refractory follicular lymphoma: updated analysis of the ROSEWOOD study

Resúmenes

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC) Comparative efficacy of zanubrutinib (ZANU) versus rituximab (RTX) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC) First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS) MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL) Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US) Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: zanidatamab in previously- treated HER2-amplified biliary tract cancer (BTC) Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 European/North American (EU/NA) subgroup Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a Phase Ib/II study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Mayo 2023

ISPOR (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)

Abril 2023

BSH (Sociedad Británica de Hematología)

BSH (Sociedad Británica de Hematología)

Abril de 2023 (Birmingham, Inglaterra)
Abril 2023

AACR (Asociación Estadounidense de Investigación en Cáncer)

AACR (Asociación Estadounidense de Investigación en Cáncer)

Abril de 2023 (Orlando, Florida, EE. UU.)
Marzo 2023

SFH (Sociedad Francesa de Hematología)

SFH (Sociedad Francesa de Hematología)

Marzo 2023 (París, Francia)
Marzo 2023

Hematology/Oncology Pharmacy Association (HOPA)

Marzo 2023

Cumbre de Whistler sobre neoplasias hematológicas (reuniones de oncología de DAVA)

Marzo 2023

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

Marzo 2023

JFHOD (Días francófonos de hepatogastroenterología y oncología digestiva)

Marzo 2023

JSMO (Sociedad Japonesa de Oncología Médica)

Febrero 2023

International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma (ICHM)

Febrero 2023

ASCO-GU (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Genitourinarios)

Febrero 2023

Reuniones sobre trasplante y terapia celular de ASTCT y CIBMTR (Tandem)

Enero 2023

ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)

ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)

Enero de 2023 (San Francisco, California, EE. UU.)
Diciembre 2022

ASH (Sociedad Estadounidense de Hematología)

ASH (Sociedad Estadounidense de Hematología)

Diciembre de 2022 (Nueva Orleans, Luisiana, EE. UU.)

Resúmenes

A phase 1 study evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies: preliminary data A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with non-Hodgkin lymphoma or Waldenström macroglobulinemia (WM): preliminary data A phase 1 with the novel B-cell lymphoma 2 (Bcl-1) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data Biomarker analysis of zanubrutinib and tislelizumab combination therapy in patients with relapsed/refractory B-cell malignancies Development of hypertension and atrial fibrillation following diagnosis of B-cell malignancies - a retrospective analysis of US MarketScan insurance claims database Efficacy and safety of zanubrutinib in Japanese patients with mature B-cell malignancies Genomic characterization of patients in a phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial Long-term outcomes of second-line vs later-line zanubrutinib treatment in patients with relapsed/refractory MCL: an updated pooled analysis Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia (AML) Preliminary safety and efficacy of zanubrutinib in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Preliminary safety of a Bcl-2 inhibitor, BGB-11417, in patients with relapsed/refractory multiple myeloma harboring t(11,14): a non-randomized, open-label, phase 1b/2 study Real-world evidence (RWE) studies supported hematologic oncology United States Food and Drug Administration (US FDA) approval: what do they look like? Zanubrutinib demonstrates superior progression-free survival (PFS) compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): results from final analysis of ALPINE randomized phase 3 study Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies
Diciembre 2022

ESMO-IO (Inmunooncología de la Sociedad Europea de Oncología Médica)

ESMO-IO (Inmunooncología de la Sociedad Europea de Oncología Médica)

Diciembre 2022 (Ginebra, Suiza)
Diciembre 2022

ESMO-Asia (Sociedad Europea de Oncología Médica - Asia)

ESMO-Asia (Sociedad Europea de Oncología Médica - Asia)

Diciembre de 2022 (Singapur)
Noviembre 2022

DKK (Congreso oncológico de Alemania)

Noviembre 2022

KALC (Asociación Coreana de Cáncer de Pulmón)

Noviembre 2022

SITC (Sociedad de Inmunoterapia contra el Cáncer)

Noviembre 2022

SPH (Sociedad Portuguesa de Hematología)

Noviembre 2022

ISPOR-EU (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados - Europa)

Noviembre 2022

CSCO (Sociedad China de Oncología Clínica)

CSCO (Sociedad China de Oncología Clínica)

Noviembre 2022 (China)

Resúmenes

Time to response and depth of response in non-squamous non-small cell lung cancer patients treated with tislelizumab plus chemotherapy as first line therapy: an exploratory analysis of RATIONALE-304 Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with locally advanced non-small cell lung cancer: asian versus non-asian subgroup analysis of the RATIONALE-303 study RATIONALE-304: tislelizumab plus chemotherapy versus chemotherapy alone as first line treatment for nonsquamous non-small cell lung cancer in patients aged 65-75 years Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma A matching-adjusted indirect comparison of tislelizumab versus camrelizumab as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM) AdvanTIG-105: a phase 1 dose-verification study of ociperlimab in combination with tislelizumab in advanced solid tumors in Chinese patients AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer AdvantTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic non-small cell lung cancer HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive advanced or metastatic gastroesophageal adenocarcinoma Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML) Rationale-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction cancer The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen Tislelizumab versus docetaxel in patients with previously treated advanced nonsquamous non-small cell lung cancer: subanalysis from the RATIONALE-303 phase 3 randomized clinical study Tislelizumab versus docetaxel in patients with previously treated advanced squamous non-small cell lung cancer: sub-analysis from phase 3 RATIONALE-303 randomized clinical study Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303 Zanubrutinib plus obinutuzumab (ZO) vs obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
Noviembre 2022

COSA (Sociedad Australiana de Oncología Clínica)

Octubre 2022

IWWM (Taller internacional sobre la macroglobulinemia de Waldenström)

IWWM (Taller internacional sobre la macroglobulinemia de Waldenström)

Octubre 2022 (Madrid, España)
Octubre 2022

JSCO (Sociedad Japonesa de Oncología Clínica)

Octubre 2022

Linfoma, leucemia y mieloma (LLM)

Octubre 2022

JSH (Sociedad Japonesa de Hematología)

Octubre 2022

DGHO (Sociedades Alemana, Austríaca y Suiza de Hematología y Oncología Médica)

DGHO (Sociedades Alemana, Austríaca y Suiza de Hematología y Oncología Médica)

Octubre 2022 (Viena, Austria)
Octubre 2022

SEHH (Sociedad Española de Hematología y Hemoterapia)

SEHH (Sociedad Española de Hematología y Hemoterapia)

Octubre 2022 (Barcelona, España)
Septiembre 2022

SOHO (Sociedad de Oncología Hematológica)

SOHO (Sociedad de Oncología Hematológica)

Septiembre de 2022 (Houston, Texas, EE. UU.)
Septiembre 2022

SIE (Sociedad Italiana de Hematología)

SIE (Sociedad Italiana de Hematología)

Septiembre 2022 (Roma, Italia)
Septiembre 2022

NZSO (Sociedad de Oncología de Nueva Zelanda)

Septiembre 2022

HSANZ (Sociedad de Hematología de Australia y Nueva Zelanda)

HSANZ (Sociedad de Hematología de Australia y Nueva Zelanda)

Septiembre 2022 (Sídney, Australia)
Septiembre 2022

ESMO (Sociedad Europea de Oncología Médica)

ESMO (Sociedad Europea de Oncología Médica)

Septiembre 2022 (París, Francia)
Septiembre 2022

PTHiT (Sociedad Polaca de Hematología y Medicina Transfusional)

Septiembre 2022

KSMO (Sociedad Coreana de Oncología Médica)

Agosto 2022

WCLC (World Congress on Lung Cancer)

Julio 2022

PPLC (Pan Pacific Lymphoma Conference)

Junio 2022

WCGI (World Congress on Gastrointestinal Cancer)

Junio 2022

AOS (Sociedad Asiática de Oncología)

Junio 2022

EHA (Asociación Europea de Hematología)

EHA (Asociación Europea de Hematología)

Junio 2022 (Viena, Austria)

Pósteres

A phase 1 first‑In‑human study of BGB‑16673, a Bruton tyrosine kinase protein degrader, in patients with B‑cell malignancies (trial in progress) A phase 1 study with the novel BCL2 Inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial View Summary of Poster in Plain Language Patient-reported outcomes from a phase 3 randomized study of zanubrutinib vs bendamustine plus rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) View Summary of Poster in Plain Language Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme data set Preliminary safety and efficacy of BGB‑11417, a potent and selective B‑cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma Real-world treatment patterns and economic burden of patients with marginal zone lymphoma Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia Tislelizumab, a PD‑1 inhibitor for relapsed/refractory mature (NK)/T‑cell neoplasms: results from a phase 2 study Zanubrutinib in older patients with relapsed/refractory marginal zone lymphoma (MZL): subgroup analysis of the Magnolia study

Resúmenes

A phase 1 first in-human study of BGB-16673, a Bruton tyrosine kinase protein degrader, in patients (pts) with B-cell malignancies (trial in progress) A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with B-cell malignancies: preliminary data Efficacy of first-line treatment for chronic lymphocytic leukemia: a bayesian network meta-analysis Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia Patient-reported outcomes from a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) CLL/SLL Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML) Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma Real-world treatment patterns and economic burden of patients with marginal zone lymphoma Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia Treatment persistence and adherence to ibrutinib in patients with Waldenstrӧm macroglobulinemia: a German claims data analysis Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies Zanubrutinib in older patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): subgroup analysis of the MAGNOLIA study
Junio 2022

ASCO (Sociedad Estadounidense de Oncología Clínica)

ASCO (Sociedad Estadounidense de Oncología Clínica)

Junio de 2022 (Chicago, Illinois, EE. UU.)

Resúmenes

A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM) ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM) AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC) Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208 Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208 Efficacy of first-line treatment for chronic lymphocytic leukemia: a Bayesian network meta-analysis Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC), RATIONALE 302: Asia subgroup Real world evidence of impact of atrial fibrillation (AF) on clinical and economic outcomes in patients with chronic lymphocytic leukemia (CLL) Real-world (RW) treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors (BTKi) in patients (pts) with mantle cell lymphoma (MCL) Real-world treatment (tx) patterns and economic burden of patients (pts) with marginal zone lymphoma (MZL) Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL) Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: results from a phase 2 study Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): preliminary results from a phase 1b/2 study Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: preliminary results from a phase 1b/2 study Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
Mayo 2022

ISPOR (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)

Mayo 2022

ICCEH (International Conference on Clinical and Experimental Hematology)

Abril 2022

TCT (Transplantation & Cellular Therapy)

Abril 2022

Programa de la serie plenaria de ASCO (Sociedad Estadounidense de Oncología Clínica)

Abril 2022

AACR (Asociación Estadounidense de Investigación en Cáncer)

AACR (Asociación Estadounidense de Investigación en Cáncer)

Abril de 2022 (Nueva Orleans, Luisiana, EE. UU.)
Abril 2022

BSH (Sociedad Británica de Hematología)

Marzo 2022

SIES (Sociedad Italiana de Hematología Experimental)

Marzo 2022

KSH (Sociedad Coreana de Hematología)

Marzo 2022

ELCC (Congreso Europeo de Cáncer de Pulmón)

Marzo 2022

SFH (Sociedad Francesa de Hematología)

Marzo 2022

SGO (Sociedad de Oncología Ginecológica)

Marzo 2022

JFHOD (Días francófonos de hepatogastroenterología y oncología digestiva)

Marzo 2022

ESMO TAT (Terapias oncológicas dirigidas de la Sociedad Europea de Oncología Médica)

Febrero 2022

JSMO (Sociedad Japonesa de Oncología Médica)

Enero 2022

BTOG (Grupo Británico de Oncología Torácica)

Enero 2022

ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)

ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)

Enero de 2022 (San Francisco, California, EE. UU.)

Pósteres

AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 (PD-L1) AdvanTIG-206: anti-TIGIT monoclonal antibody ociperlimab + anti-PD-1 monoclonal antibody tislelizumab + BAT1706 vs tislelizumab + BAT1706 as first-line treatment for unresectable hepatocellular carcinoma Clinical outcomes associated with tislelizumab in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib or lenvatinib in RATIONALE-208 Clinical outcomes in patients with previously treated advanced hepatocellular carcinoma experiencing hepatitis B virus DNA increases during tislelizumab treatment in RATIONALE-208 DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life Updated analysis from a phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors

Resúmenes

AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1) AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 vs TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC) Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208 Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208 DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC) Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL) Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
Diciembre 2021

ASH (Sociedad Estadounidense de Hematología)

ASH (Sociedad Estadounidense de Hematología)

Diciembre 2021 (Atlanta, Georgia, Estados Unidos)